Noticias de Washington DC para el mundo

Inicio
Actualidad
- Latin News
- BW
  - Directorio
DMV
Opinión
Entretenimiento
Deportes
Quiénes Somos
- Archivo

Inicio
Actualidad
- Latin News
- BW
  - Directorio
DMV
Opinión
Entretenimiento
Deportes
Quiénes Somos
- Archivo

Home
Actualidad
Hurricane Wilma is category 4

Hurricane Wilma is category 4

15 años ago476< 1 Min Read

Facebook Twitter LinkedIn Pinterest Stumbleupon Email

Share

Previous PostBarclays’ Bob Diamond defends

Next PostHealth care reform and protests

Artículos Relacionados

Reuters informa que Trump está a punto de ofrecer a Arabia Saudí un multimillonario paquete de armas

Yanko Farias6 horas ago

Foto cortesía El Gobierno de Trump está a punto de ofrecer a Arabia Saudí un acuerdo armamentístico por un valor de más de 100 mil millones de dólares. La agencia de noticias...
Supuesto ladrón del bolso de la secretaria de Seguridad Nacional es detenido

Yanko Farias16 horas ago

Foto ilustrativa no relacionada con el caso del robo a Kristi Noem. Foto Google. Redacción ML Noticias Un sospechoso que se cree es la persona que robó el bolso de la secreta...
Más de 200 mil personas despiden al Papa Francisco en la Plaza San Pedro

Yanko Farias1 día ago

El ataúd a punto de ser colocado en el carro fúnebre camino a la Basílica de Santa María la Mayor. Foto captura de pantalla Redacción ML Noticias Desde muy temprano de este s...

Archivos

Archivos

LO ÚLTIMO

Popular

Tendencia

Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI

Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI

53 minutos ago

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

53 minutos ago

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

1 hora ago

GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights

GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights

2 horas ago

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

2 horas ago

FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights

FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights

3 horas ago

Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI

Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI

53 minutos ago

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

53 minutos ago

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

1 hora ago

GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights

GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights

2 horas ago

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

2 horas ago

FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights

FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights

3 horas ago

Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI

Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI

53 minutos ago

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

53 minutos ago

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

1 hora ago

GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights

GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights

2 horas ago

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

2 horas ago

FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights

FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights

3 horas ago

Bienvenidos a Metro Latino USA, su portal de noticias.

ÚLTIMA HORA

Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI

27 de abril de 2025
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

27 de abril de 2025
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

27 de abril de 2025

Categorias

Actualidad (16242)
()
Comunidad (2810)
Entretenimiento (2683)
Deportes (1179)
DMV (1510)
Latin News (403)
Latinoamérica y Mundo (3733)
Maryland (1050)
Opinión (2902)
Virginia (891)

Publicidad

Estamos en

Washington DC.

Website

www.metrolatinousa.com

Escríbenos

[email protected]

© 2024 MetroLatinoUSA.com. Todos los derechos reservados.

¡Síguenos en Facebook!

¡Síguenos en Twitter!

Metro Latino

Metro Latino USA

Metro Latino USA es un sitio informativo digital fundado en 2007 en el área de Washington, DC para crear conciencia ciudadana y sumarse a llamados a la acción con las nuevas plataformas disponibles online.

¡Síguenos!

¡Contáctenos!

[email protected]
www.metrolatinusa.com
Lun-Vier : 8:00 am - 5:00 pm